Physician
Siddiqui, Zaki
Siddiqui, Zaki was paid $3.16M by Medicaid between Jan 2018 and Dec 2024, across 73 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 30% of everything it billed.
33Billing provider infoSIDDIQUI, ZAKI
CHICAGO, IL 60625
CHICAGO, IL 60625
33aNPI1366534729assigned 09/29/2006
33bProvider typePediatrics Physician
28Total paid$3.16M
24GClaims95,709
24DCodes billed73
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#22 of 1,805
Median peer was paid$55K
This provider vs. median57×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,064 | $464K | |
| 2019 | 17,801 | $539K | |
| 2020 | 13,951 | $434K | |
| 2021 | 16,742 | $532K | |
| 2022 | 13,785 | $493K | |
| 2023 | 10,289 | $372K | |
| 2024incomplete | 8,077 | $329K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 19,873 | 17,200 | $954K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 4,412 | 3,790 | $323K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 9.6% | 4,014 | 3,372 | $305K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.1% | 3,752 | 3,058 | $287K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 8.4% | 3,194 | 2,770 | $267K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.4% | 2,972 | 2,424 | $204K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.4% | 6,790 | 5,719 | $108K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 4,099 | 3,751 | $101K |
| 92015 | Determination of refractive state | 2.4% | 4,305 | 3,850 | $76K |
| 92587 | 1.9% | 4,055 | 3,205 | $59K | |
| 90670 | 1.3% | 1,917 | 1,617 | $40K | |
| 83655 | 1.1% | 3,018 | 2,449 | $34K |
61 more codes
| 90686 | <1% | 2,602 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,256 | $24K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 678 | $23K |
| 90734 | <1% | 1,182 | $19K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 423 | $19K |
| 90700 | <1% | 1,684 | $17K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 315 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,038 | $15K |
| 90647 | <1% | 1,460 | $15K | |
| 90680 | <1% | 1,336 | $15K | |
| 90651 | <1% | 618 | $15K | |
| 90716 | <1% | 783 | $12K | |
| 90633 | <1% | 1,199 | $12K | |
| 0002A | <1% | 273 | $11K | |
| 88738 | <1% | 2,529 | $11K | |
| 90677 | <1% | 264 | $10K | |
| 0001A | <1% | 222 | $9K | |
| 90707 | <1% | 791 | $9K | |
| 90715 | <1% | 626 | $9K | |
| 90713 | <1% | 887 | $8K | |
| 90744 | <1% | 761 | $8K | |
| 0071A | <1% | 167 | $7K | |
| 90658 | <1% | 833 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 265 | $7K |
| 99460 | <1% | 134 | $7K | |
| 0072A | <1% | 158 | $7K | |
| 0003A | <1% | 147 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 41 | $6K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 75 | $5K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 121 | $5K |
| 86580 | <1% | 946 | $4K | |
| D1206 | Topical application of fluoride varnish | <1% | 166 | $4K |
| 85018 | <1% | 1,681 | $4K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 39 | $3K |
| 90621 | <1% | 105 | $3K | |
| 0012A | <1% | 56 | $2K | |
| 99381 | <1% | 27 | $2K | |
| 81002 | <1% | 749 | $2K | |
| 91300 | <1% | 262 | $2K | |
| 90672 | <1% | 217 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 47 | $1K |
| 0011A | <1% | 45 | $1K | |
| 99422 | <1% | 49 | $1K | |
| 99383 | <1% | 12 | $1K | |
| 90723 | <1% | 90 | $1K | |
| 90685 | <1% | 140 | $1K | |
| 90620 | <1% | 60 | $923.40 | |
| 90698 | <1% | 82 | $896.56 | |
| 90671 | <1% | 21 | $776.47 | |
| 93000 | <1% | 34 | $753.10 | |
| 86769 | <1% | 17 | $716.21 | |
| 94664 | <1% | 49 | $714.40 | |
| 91301 | <1% | 78 | $595.39 | |
| 0013A | <1% | 13 | $505.68 | |
| 99421 | <1% | 26 | $316.56 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 18 | $232.00 |
| 90657 | <1% | 47 | $180.50 | |
| 90710 | <1% | 13 | $163.28 | |
| 86308 | <1% | 23 | $108.00 | |
| 91307 | <1% | 155 | $45.29 | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 0% | 173 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.